Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES ANICURA IN CONNECTION WITH THE ACQUISITION OF DJURKLINIKEN I KATRINEHOLM
Mandate

VINGE ADVISES ANICURA IN CONNECTION WITH THE ACQUISITION OF DJURKLINIKEN I KATRINEHOLM

April 22, 2014

Vinge has advised AniCura (formerly Djursjukhusgruppen) in connection with the acquisition of Djurkliniken i Katrineholm Aktiebolag. AniCura is a leader in advanced veterinary care for dogs, cats and other companion animals. Established in 2011, AniCura is the first merger of companion animal hospitals in the Nordic region and is currently the only Nordic veterinary care group exclusively focused on companion animals.

Vinge’s team consisted of partner Jonas Bergström together with, among others, associates Gustav Jönsson, Erik Claesson, Niclas Winnberg and Emelie Klefbeck.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026